Chronic use of renin‐angiotensin‐aldosterone system blockers and mortality in COVID‐19: A multicenter prospective cohort and literature review
暂无分享,去创建一个
V. Gaborieau | A. Sommet | R. Favory | J. Payen | D. Luton | Y. Yazdanpanah | S. Rebaudet | J. Timsit | L. Lefebvre | H. Le Nagard | N. Benech | D. Costagliola | J. Hulot | L. Abel | L. Bouadma | M. Esposito‐Farèse | J. Lucet | P. Rossignol | E. L’her | H. Mouquet | L. Plantier | C. Tromeur | R. Borie | C. Flateau | S. Diamantis | M. Jourdain | A. Kimmoun | A. Guillaumot | F. Retornaz | L. Bodénes | L. Mandelbrot | B. Cholley | D. Deplanque | S. Nseir | K. Faure | F. Djossou | J. Lelièvre | M. Rosa-Calatrava | B. Lina | A. Gaymard | S. van der Werf | B. Dussol | E. Vidal-Petiot | D. Malvy | F. Lescure | V. Enouf | J. Mullaert | N. Néant | G. Peytavin | D. Descamps | B. Rammaert | C. Ficko | E. D’Ortenzio | S. Thiberville | A. Scherpereel | G. Martin-Blondel | P. Delobel | M. Debray | A. Khalil | B. Sarton | J. Guedj | R. Basmaci | O. Launay | H. Esperou | F. Bissuel | N. Peiffer-Smadja | François Téoulé | D. Guellec | K. Lacombe | B. Pastene | Q. Le Hingrat | M. Mezidi | V. Gissot | A. Sotto | J. Poissy | P. Tattevin | E. Botelho-Nevers | A. Gagneux-Brunon | P. Bolze | F. Mentré | A. Chéret | V. Lemée | O. Lairez | S. Ansart | J. Arlet | T. Flament | A. Wiedemann | X. Duval | J. Dimet | M. Le Maréchal | Paul-Henri Wicky | C. Couffignal | A. Boureau | D. Garot | L. Guilleminault | I. Gorenne | M. Lagrange | V. Le Moing | S. Le Gac | H. Cordel | S. Jauréguiberry | S. Redl | C. Rabaud | L. Bitker | É. Senneville | S. Préau | L. Piroth | J. Inamo | F. Angoulvant | J. Diehl | D. Zucman | L. Bouillet | O. Terrier | O. Bouchaud | N. Ouamara | N. Terzi | O. Lesens | H. Salvator | C. Laouénan | F. Goehringer | A. Cabié | B. Visseaux | W. Picard | S. Greffe | O. Epaulard | M. Maillet | C. Semaille | C. Chirouze | C. Andrejak | O. Picone | C. Salmon Gandonnière | S. Tubiana | P. Loubet | O. Robineau | D. Laureillard | T. Goulenok | L. Maulin | Q. Lepiller | C. Tardivon | Victoria Manda | E. de Montmollin | C. Roy | V. Garrait | J. Sibiude | E. Polard | K. Bouiller | B. Lefebvre | F. Kaguelidou | T. Perpoint | P. Roger | C. Rapp | A. Ducancelle | J. Turmel | B. Rozé | F. Dubos | J. Ghosn | É. Demonchy | K. Risso | Y. Kerroumi | V. Meyssonnier | L. Deconinck | S. Bessis | F. Vuotto | V. Dubée | A. Meybeck | Théo Trioux | C. Allavena | G. Colin | C. Tual | A. Veislinger | M. Revest | H. Hitoto | M. Martinot | N. Sedillot | H. Yonis | A. Lemaignen | A. Conrad | N. Dournon | M. Doret‐Dion | K. Didier | D. Bachelet | Stella Rousset | V. Langlois | G. Louis | V. Peigne | E. Curlier | M. Livrozet | M. Isnard | J. Jabot | C. Dorival | F. Bompart | K. Alexandre | M. Etienne | A. Bousquet | D. Bregeaud | J. Chapplain | D. Ponscarme | M. Hentzien | G. Le Moal | A. Diallo | J. Assié | C. Yelnik | A. Debard | Minerva Cervantes-Gonzalez | R. Mahieu | P. Le Turnier | M. Bouscambert | D. Larivière | E. Mercier | S. Markowicz | K. Delavigne | E. Oziol | S. Le Mestre | Aurélie Papadopoulos | G. Macheda | F. Bani-Sadr | T. Guimard | O. Sanchez | H. Aumaître | Bruno Lévy | I. Fabre | Marielly Casanova | M. Leone | J. Patrier | Duc Nguyen | J. Mankikian | M. Murris | M. Blot | S. Mahy | J. Chas | R. Guery | H. Drouet | D. Bouhour | M. Lachâtre | S. Bévilacqua | R. Hamidfar | P. Rispal | M. Roriz | N. Gault | M. Lambert | Charlène Da Silveira | K. Bhavsar | L. Luong | N. Saidani | I. Hoffmann | N. Mercier | Valentine Campana | N. Ferrière | V. Pestre | Adrien Auvet | N. Allou | B. Elharrar | T. Carmoi | C. Azoulay | Marie Bartoli | Sylvie Behilill | Marine Beluze | D. Benkerrou | Anissa Chair | A. Coelho | Mathilde Desvallée | P. Eloy | Tristan Gigante | M. Gilg | Alexandre Hoctin | I. Houas | S. Jaafoura | Ouifiya Kafif | Sabrina Kali | Coralie Khan | F. Lainé | Samira Laribi | Minh Lê | Cyril Le Bris | G. Lingas | Moïse Machado | Marina Mambert | Al Manuel | Amina Meziane | Marion Noret | C. Paul | Oriane Puéchal | Bénédicte Rossignol | M. Schneider | N. Vanel | C. Vauchy | P. Dunand | Cécile Goujard | I. Delacroix | M. Gominet | Justine Pages | S. Bouchez | S. Stabler | C. Joseph | E. Soum | Y. Ait Tamlihat | Johann Auchabie | Laurène Azemar | Claudine Badr | Jules Bauer | A. Bedossa | K. Bézulier | Anne‐Hélène Boivin | Axelle Braconnier | M. Buisson | Cyril Cadoz | Nicolas Carlier | F. Catherine | Catherine Chakveatze | Thibault Chiarabini | Marie‐Charlotte Chopin | Grégory Corvaisier | S. Cousse | Corinne Daniel | Romain Decours | Eric Delaveuve | V. Dinot | Fara Diop | I. Enderle | Nadia Ettalhaoui | Eglantine Ferrand Devouge | E. Fourn | R. Gaci | J. Gagnard | G. Giordano | Laure Goubert | A. Hachemi | Hajnal-Gabriela Illes | P. Imbert | Danielle Jaafar | Coline Jaud‐Fischer | Florence Jego | A. Kpangon | M. Lacoste | S. Lasry | C. Le Bihan | G. Le Falher | B. Lefèvre | A. Lemeur | Geoffrey Liegeon | Oryane Mabiala | T. Maitre | Thierry Mazzoni | Antoine Merckx | Clara Mouton Perrot | J. Moyet | Elsa Nyamankolly | R. Ouissa | M. Pagadoy | N. Pansu | J. Pasquier | Florent Peelman | Carola Pierobon | I. Pironneau | R. Pokeerbux | Anne-Sophie Resseguier | L. Richier | J. Romaru | Stéphane Sallaberry | Nassima Si Mohammed | Lysa Tagherset | B. Thill | N. Tissot | T. Trouillon | Jeanne Truong | A. Valran | N. De Castro | Mayka Mergeayfabre | Lucie Lefèvre | Marie‐Christine Carret | Guylaine Castor‐Alexandre | T. Chiarabini | S. Couffin‐Cadiergues | R. Courtois | Hajnal‐Gabriela Illes | Marie Langelot‐Richard | Cécile Mear‐Passard | V. Petrov‐Sanchez | S. Rousset | Pierre‐François Sandrine | Marie‐Capucine Tellier | Matthieu Lesouhaitier | C. Rames | Camille Bouisse | M. Bennani | Aurélie Martin | A. Barrelet | A. Diouf | S. Fry | B. Loutfi | Y. N’Guyen | Yves Lévy | P. Granier | B. Lefévre | J. Zabbe | Camille Chassin | E. Le Coustumier | Marie Alpha Soizic Noémie Christelle Ventzislava Claire Bartoli Diallo Le Mestre Mercier Paul Petro | Claire Léy‐Marchal | Maximilen Saint Gilles | Céline Michelangelli | Pierre Jacquet | Elise Artaud‐Maccari | Marie‐Laure Chabi‐Chavillat | P. Caraux Paz | J. Auchabie | M. Noret | M. Esposito-farese | S. Couffin-cadiergues | M. Machado | Cécile Azoulay | S. Laribi | V. Petrov-sanchez | Juliette Patrier | Rostane Gaci | Simon-djamel Thiberville | Maïder Pagadoy | A. Auvet | Hervé Le Nagard | Muriel Doret‐Dion | Karine Bézulier | C. Goujard | Marie Lacoste | Isabelle Pironneau | Ryadh Pokeerbux | Amélie Valran | Laurent Guilleminault | N. Peiffer‐Smadja | Samuel Markowicz | Dehbia Benkerrou | A. Chair | Fanny Vuotto | O. Puéchal | M. Tellier | C. Laouénan | Charléne Da Silveira | Romain Basmaci | Charlotte Salmon Gandonnière | Vincent Pestre | Jimmy Mullaert | Mehdi Mezidi
[1] P. Whelton,et al. Renin–angiotensin-system inhibitors and all-cause mortality in patients with COVID-19: a systematic review and meta-analysis of observational studies , 2021, Journal of hypertension.
[2] C. Granger,et al. Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial. , 2021, JAMA.
[3] T. Chang,et al. Continuation versus discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial , 2021, The Lancet Respiratory Medicine.
[4] L. Lund,et al. Association between renin–angiotensin–aldosterone system inhibitor use and COVID‐19 hospitalization and death: a 1.4 million patient nationwide registry analysis , 2020, European journal of heart failure.
[5] B. Hocher,et al. Comparison of infection risks and clinical outcomes in patients with and without SARS‐CoV‐2 lung infection under renin–angiotensin–aldosterone system blockade: Systematic review and meta‐analysis , 2020, British journal of clinical pharmacology.
[6] J. Rigdon,et al. Evaluating sources of bias in observational studies of angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker use during coronavirus disease 2019: beyond confounding. , 2020, Journal of hypertension.
[7] A. Sommet,et al. Outcome of patients hospitalized for COVID‐19 and exposure to angiotensin‐converting enzyme inhibitors and angiotensin‐receptor blockers in France: results of the ACE‐CoV study , 2020, Fundamental & clinical pharmacology.
[8] Y. Yazdanpanah. Impact on disease mortality of clinical, biological, and virological characteristics at hospital admission and overtime in COVID‐19 patients , 2020, Journal of medical virology.
[9] V. Vassiliou,et al. Effect of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with COVID-19: a Systematic Review and Meta-analysis of 28,872 Patients , 2020, Current Atherosclerosis Reports.
[10] J. Moslehi,et al. Mortality and Pre‐Hospitalization use of Renin‐Angiotensin System Inhibitors in Hypertensive COVID‐19 Patients , 2020, Journal of the American Heart Association.
[11] Jesús Piqueras-Flores,et al. Comparative analysis between the use of renin–angiotensin system antagonists and clinical outcomes of hospitalized patients with COVID-19 respiratory infection , 2020, Medicina Clínica (English Edition).
[12] A. Singer,et al. Continued In-Hospital Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use in Hypertensive COVID-19 Patients Is Associated With Positive Clinical Outcome , 2020, The Journal of infectious diseases.
[13] D. D. de Lange,et al. Inhibitors of the renin–angiotensin–aldosterone system and COVID-19 in critically ill elderly patients , 2020, European heart journal. Cardiovascular pharmacotherapy.
[14] R. Cianci,et al. Age and Multimorbidity Predict Death Among COVID-19 Patients , 2020, Hypertension.
[15] C. Torp‐Pedersen,et al. Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality. , 2020, JAMA.
[16] A. Grover,et al. A systematic review and meta-analysis to evaluate the clinical outcomes in COVID-19 patients on angiotensin-converting enzyme inhibitors or angiotensin receptor blockers , 2020, European heart journal. Cardiovascular pharmacotherapy.
[17] Y. Mahjoub,et al. Association between renin–angiotensin system inhibitors and COVID-19 complications , 2020, European heart journal. Cardiovascular pharmacotherapy.
[18] A. Daugherty,et al. Effects of Renin-Angiotensin Inhibition on ACE2 and TMPRSS2 Expression: Insights into COVID-19 , 2020, bioRxiv.
[19] G. Condorelli,et al. Continuation versus discontinuation of ACE inhibitors or angiotensin II receptor blockers in COVID-19: effects on blood pressure control and mortality , 2020, European heart journal. Cardiovascular pharmacotherapy.
[20] P. Serruys,et al. Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study , 2020, European heart journal.
[21] A. Pickles,et al. Angiotensin‐converting enzyme inhibitors and angiotensin II receptor blockers are not associated with severe COVID‐19 infection in a multi‐site UK acute hospital trust , 2020, European journal of heart failure.
[22] Yuan Hong,et al. Decreased Mortality of COVID-19 with Renin-Angiotensin-Aldosterone System Inhibitors Therapy in Patients with Hypertension: A Meta-Analysis. , 2020, Hypertension.
[23] Sun-Young Jung,et al. Association of Renin-angiotensin-aldosterone System Inhibitors With Coronavirus Disease 2019 (COVID-19)- Related Outcomes in Korea: A Nationwide Population-based Cohort Study , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[24] Jiong Yu,et al. ACEI/ARB use and risk of infection or severity or mortality of COVID-19: A systematic review and meta-analysis , 2020, Pharmacological Research.
[25] L. Rodríguez-Mañas,et al. Use of renin–angiotensin–aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study , 2020, The Lancet.
[26] P. Ponikowski,et al. Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin–angiotensin–aldosterone inhibitors , 2020, European heart journal.
[27] J. Sterne,et al. Collider bias undermines our understanding of COVID-19 disease risk and severity , 2020, Nature Communications.
[28] Sung Yang,et al. Association Between Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19 Infection in South Korea , 2020, Hypertension.
[29] M. Chung,et al. Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19). , 2020, JAMA cardiology.
[30] G. Mancia,et al. Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19 , 2020, The New England journal of medicine.
[31] C. Borghi,et al. Clinical impact of renin-angiotensin system inhibitors on in-hospital mortality of patients with hypertension hospitalized for COVID-19 , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[32] Jian Chen,et al. Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China. , 2020, JAMA cardiology.
[33] Eun Ji Kim,et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. , 2020, JAMA.
[34] Qingbo Xu,et al. Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19 , 2020, Circulation research.
[35] Ji-Guang Wang,et al. Hypertension, the renin–angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19 , 2020, Cardiovascular research.
[36] Xin Li,et al. COVID-19 with Different Severities: A Multicenter Study of Clinical Features , 2020, American journal of respiratory and critical care medicine.
[37] J. Ge,et al. The effect of RAS blockers on the clinical characteristics of COVID-19 patients with hypertension , 2020, Annals of translational medicine.
[38] Marc A Pfeffer,et al. Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19 , 2020, The New England journal of medicine.
[39] J. Xiang,et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.
[40] Zunyou Wu,et al. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. , 2020, JAMA.
[41] Haitao Chu,et al. Effect estimates in randomized trials and observational studies: comparing apples with apples. , 2019, American journal of epidemiology.
[42] S. Cole,et al. Illustrating bias due to conditioning on a collider. , 2010, International journal of epidemiology.
[43] C. Schmid,et al. A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.
[44] D. Batlle,et al. Localization of ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using telmisartan. , 2009, American journal of physiology. Renal physiology.
[45] Mark Chappell,et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury , 2005, Nature Medicine.
[46] Arthur S Slutsky,et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure , 2005, Nature.
[47] E. McFadden,et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.
[48] Thomas Kahan,et al. [2018 ESC/ESH Guidelines for the management of arterial hypertension]. , 2019, Kardiologia polska.
[49] Yun-Cai Liu,et al. Association of the , 1995 .